Boehringer Ingelheim

Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.

One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.

A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.

6701 Kaiser Drive
Fremont, CA 94555 US

Visit website

NEWS

Business

Boehringer Ingelheim and 3BP Forge a Multi-Year Collaboration

3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by Boehringer Ingelheim.

February 22, 2019

2 min read

Alex Keown

Biotech Bay

Moderna’s Not the Only One: A Look at the mRNA Market

Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factories churning out whatever drug or molecule you program it to.

January 31, 2019

3 min read

Mark Terry

FDA

Who’s the Boss? Companies and Their Novel Drug Approvals, 2014-2018

In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.

January 15, 2019

5 min read

Mark Terry

Business

Xynomic Pharmaceuticals Picks up Second Cancer Drug From Boehringer Ingelheim in $800 Million Deal

Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II ready cancer treatment from Germany-based Boehringer Ingelheim.

December 21, 2018

2 min read

Alex Keown

Pharm Country

Top 10 Stories of 2018: BioSpace Writers Alex and Mark Pick Their Favorites

In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.

December 14, 2018

10 min read

Alex Keown and Mark Terry

Business

Following Sanofi Cuts Last Week, Boehringer Ingelheim to Cut 327 Jobs in France

More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.

December 12, 2018

2 min read

Alex Keown

Policy

What’s Going on With the Biosimilar Market?

Although a moderate presence in Europe, with about 25 biosimilars approved and on the market, they haven’t gained traction in the U.S. Even though at least 11 have been approved in the U.S., only about three are available, largely because of business tactics branded drug companies are using to slow down the competition to their typically very high-priced biologic drugs.

December 7, 2018

5 min read

Mark Terry

Policy

FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH

The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.

December 5, 2018

3 min read

Mark Terry

Business

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million up Front and $280 Million in Biobucks

Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million.

November 15, 2018

3 min read

Mark Terry

JOBS